TuisAIM • NYSEAMERICAN
add
AIM ImmunoTech Inc
Vorige sluiting
$0,36
Dagwisseling
$0,36 - $0,37
Jaarwisseling
$0,31 - $0,75
Markkapitalisasie
21,08 m USD
Gemiddelde volume
317,34 k
P/V-verhouding
-
Dividend-opbrengs
-
Marknuus
Finansieel
Inkomstestaat
Inkomste
Netto inkomste
| (USD) | Mrt. 2024info | J/J-verandering |
|---|---|---|
Inkomste | 40,00 k | -18,37% |
Bedryfskoste | 5,77 m | 32,73% |
Netto inkomste | -5,82 m | -58,89% |
Netto winsgrens | -14,54 k | -94,64% |
Wins per aandeel | -0,12 | -41,84% |
EBITDA | -5,68 m | -33,62% |
Effektiewe belastingkoers | — | — |
Balansstaat
Totale bates
Totale aanspreeklikheid
| (USD) | Mrt. 2024info | J/J-verandering |
|---|---|---|
Kontant en korttermynbeleggings | 10,94 m | -64,53% |
Totale bates | 16,19 m | -56,79% |
Totale aanspreeklikheid | 11,36 m | 359,48% |
Totale ekwiteit | 4,83 m | — |
Uitstaande aandele | 51,28 m | — |
Prys om te bespreek | 4,56 | — |
Opbrengs op bates | -80,60% | — |
Opbrengs op kapitaal | -149,88% | — |
Kontantvloei
Netto kontantverandering
| (USD) | Mrt. 2024info | J/J-verandering |
|---|---|---|
Netto inkomste | -5,82 m | -58,89% |
Kontant van bedrywe | -4,82 m | -30,84% |
Kontant van beleggings | -158,00 k | -102,56% |
Kontant van finansiering | 2,83 m | 2 729,00% |
Netto kontantverandering | -2,14 m | 41,39% |
Beskikbare kontantvloei | -2,76 m | -22,62% |
Meer oor
AIM ImmunoTech Inc., formerly known as Hemispherx Biopharma Inc., is a biopharmaceutical company based in Ocala, Florida that is focused on the research and development of therapeutics to treat multiple types of cancers, various viruses and immune-deficiency disorders. Founded in 1990, the company has twenty-three employees.
The company has created an immunomodulatory double stranded RNA drug called Ampligen.
It is also developing Ampligen to use as a treatment for multiple cancer tumor types, COVID-19 and chronic fatigue syndrome. Wikipedia
Gestig
1966
Webwerf
Werknemers
27
